Suchergebnisse - "Litton, Jennifer K"

PubPharm (22)

1

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant : ASCO Rapid Recommendation Update

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Burstein, H. | DeMichele, A. | Fallowfield, L. | +31

2

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer : ASCO Guideline Update

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Burstein, H. | Somerfield, M. | Barton, D. | +11

3

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

enthalten in: Clinical immunology (Orlando, Fla.) | 2021

von Chick, R. | Clifton, G. | Hale, D. | +13

4

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

enthalten in: Breast cancer research and treatment | 2020

von Brown, T. | Mittendorf, E. | Hale, D. | +18

5

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Clifton, G. | Hale, D. | Vreeland, T. | +10

6

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

enthalten in: Clinical immunology (Orlando, Fla.) | 2019

von Clifton, G. | Peace, K. | Holmes, J. | +8

7

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer : A Retrospective, Single Institution Experience

enthalten in: Clinical breast cancer | 2018

von Murthy, R. | Raghavendra, A. | Hess, K. | +13

8

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design

enthalten in: Clinical immunology (Orlando, Fla.) | 2018

von Jackson, D. | Trappey, F. | Clifton, G. | +9

9

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

enthalten in: Annals of surgical oncology | 2017

von Clifton, G. | Litton, J. | Arrington, K. | +6

10

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH) : a single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2017

von Rugo, H. | Seneviratne, L. | Beck, J. | +12

CommentIn: Lancet Oncol. 2017 May;18(5):564-565. - PMID 28314690